title: Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].
authors.affiliation: Ruspharmtech LLC, Saint Petersburg, Russia. Electronic address: tsimafeyeu@ruspharm.com.
authors.forename: Ilya
authors.initials: I
authors.lastname: Tsimafeyeu
authors.affiliation: Altogen Labs, Austin, TX, USA.
authors.forename: John
authors.initials: J
authors.lastname: Ludes-Meyers
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Evgenia
authors.initials: E
authors.lastname: Stepanova
authors.affiliation: FD Computing, Beerse, Belgium.
authors.forename: Frits
authors.initials: F
authors.lastname: Daeyaert
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Dmitry
authors.initials: D
authors.lastname: Khochenkov
authors.affiliation: EcoSynth, Oostende, Belgium.
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Joose
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Eliso
authors.initials: E
authors.lastname: Solomko
authors.affiliation: EcoSynth, Oostende, Belgium.
authors.forename: Koen
authors.initials: K
authors.lastname: Van Akene
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Nina
authors.initials: N
authors.lastname: Peretolchina
authors.affiliation: Altogen Labs, Austin, TX, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Yin
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Oxana
authors.initials: O
authors.lastname: Ryabaya
authors.affiliation: Moscow Clinical and Research Center, Moscow, Russia.
authors.forename: Mikhail
authors.initials: M
authors.lastname: Byakhov
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
authors.forename: Sergei
authors.initials: S
authors.lastname: Tjulandin